• Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Daily Dose: Tirzepatide Leads to 15% Weight Loss in Adults with Obesity, T2D


Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.

On June 23, 2023, we reported on a study presented at the 83rd Scientific Sessions of the American Diabetes Association® and simultaneously published in The Lancet.

The study

SURMOUNT-2, a randomized placebo-controlled phase 3 clinical trial was designed to evaluate how tirzepatide, a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, affects body weight in overweight individuals with type 2 diabetes (T2D).

Investigators randomly assigned 938 participants who had T2D and who had overweight or obesity in a 1:1:1 ratio to receive tirzepatide 10 mg, tirzepatide 15 mg, or placebo. The coprimary endpoints were mean percent change from baseline in body weight and the percentage of participants who achieve a reduction in body weight of at least 5%, both outcomes evaluated through 72 weeks.

The findings

Investigators reported that participants in the groups treated with tirzepatide 10 and 15 mg lost an average of 15% of starting body weight after 72 weeks of treatment. Overall mean weight loss among tirzepatide-treated patients was 14.8 kg or 33 pounds. Mean baseline HbA1c of 8% was reduced to 5.9% at week 72. Moreover, the researchers found that half (49%) of SURMOUNT-2 participants who received tirzepatide reach a normal HbA1c of less than 5.7% without no reports of severe hypoglycemia.

Click here for more details.

Related Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
© 2024 MJH Life Sciences

All rights reserved.